Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Womens HealthAWHL -2.96%38 3-Year ROIIC % is 145,156.25 as of Dec. 2025. GuruFocus rates AWHL with a GF Score™ of 38/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Aspira Womens Health ranks better than 99.51% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Aspira Womens Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 145,156.25%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Aspira Womens Health's 3-Year ROIIC % or its related term are showing as below:
AWHL's 3-Year ROIIC % is ranked better than 99.51% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs AWHL: 145156.25
Aspira Womens Health (OTCPK:AWHL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Aspira Womens Health 3-Year ROIIC % Related Terms
Aspira Womens Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AWHL vs MDXH, BIOQ, XWEL: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's 3-Year ROIIC % falls into.
Aspira Womens Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -7.913 (Dec. 2025) - -31.138 (Dec. 2022) )
/
( 2.324 (Dec. 2025) - 2.308 (Dec. 2022) )
=
23.225
/
0.016000000000001
=
145,156.25%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Aspira Womens Health (AWHL) has a 3-Year ROIIC % of 145,156.25 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aspira Womens Health and its competitors. According to the industry distribution chart, Aspira Womens Health ranks #1 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Aspira Womens Health's 3-Year ROIIC % too high?
Aspira Womens Health's current 3-Year ROIIC % is 145,156.25. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.13. Aspira Womens Health's value of 145,156.25 is 116124900% above this industry median. Based on the distribution chart, Aspira Womens Health ranks #1 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Aspira Womens Health has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's 3-Year ROIIC % compare to MDXH and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #1 out of 204 companies for 3-Year ROIIC %. This places Aspira Womens Health in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.13. Aspira Womens Health's value of 145,156.25 is 116124900% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Womens Health's current 3-Year ROIIC % of 145,156.25 is 116124900% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current 3-Year ROIIC % is 145,156.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.39 — trading 38.6% above its estimated fair value. The current 3-Year ROIIC % is 145,156.25 and 116124900% above the Medical Diagnostics & Research industry median of 0.13. Aspira Womens Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current 3-Year ROIIC % is 145,156.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.39 is trading 38.6% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
3-Year ROIIC %: 145,156.25
GF Value™: $0.28 vs. price of $0.39 (38.6% above fair value)
Industry Position: 116124900% above the Medical Diagnostics & Research median (#1 of 204)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
38GF Score
Get the complete analysis for AWHL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
